WuXi to create $200m investment fund following initial success

By Zachary Brennan

- Last updated on GMT

Related tags Investment

WuXi to create $200m investment fund following initial success
The almost-private China-based CDMO (contract development and manufacturing organization) WuXi is looking to reap larger rewards from investing in US and China pharma and biotech firms.

The new $200m venture fund, known as WuXi Healthcare Ventures II and outlined in a SEC filing​, will be four times as large as a previous $50m fund that has already made gains for the busy company.

With an initial focus on technology and life-science companies, the first WuXi fund from 2011, as of December 31, 2014, made $36.1m in investments, including $32.5m for biopharma companies and industry funds of $3.6m. WuXi says it has already “realized $23.6m in gains from three portfolio companies into which we had made $7m of investments​.”

Investment activities at the fund are overseen primarily by Edward Hu, CFO and Chief Investment Officer, with the assistance of a group of investment professionals and Ge Li, Chairman, CEO and Founder of WuXi, the company said in a SEC filing​.

In addition to providing favorable investment returns, our corporate venture fund has allowed us to monitor developments in the life-sciences industry and has provided opportunities for us to successfully market our services to a range of potential customers. Many of our portfolio companies have used WuXi’s drug discovery and development services​,” the company said.

The opportunity for outside investments comes as the company is investing internally too. Last week, WuXi announced it raised $80m for its small molecule manufacturing subsidiary​, which offers intermediates and APIs (active pharmaceutical ingredients) for clients. The company has also begun construction on what is expected to be the largest mammalian cell culture manufacturing site​ in the world and will be complete by 2017.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars